Pulmonary Complications of Everolimus in Liver Transplant Patients: A 10-Year Experience.

Autor:	Obri MS; Internal Medicine, Henry Ford Health System, Detroit, USA., Fahoury AM; Internal Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, USA., Alhaj Ali S; Internal Medicine, Henry Ford Health System, Detroit, USA., Samad M; Internal Medicine, Henry Ford Health System, Detroit, USA., Alluri S; Internal Medicine, Henry Ford Health System, Detroit, USA., Obri AS; Pharmacy, College of Pharmacy, University of Toledo, Toledo, USA., Almajed MR; Internal Medicine, Henry Ford Health System, Detroit, USA., Harris KB; Gastroenterology, Henry Ford Health System, Detroit, USA., Jafri SM; Gastroenterology and Hepatology, Henry Ford Health System, Detroit, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Jan 31; Vol. 16 (1), pp. e53334. Date of Electronic Publication: 2024 Jan 31 (Print Publication: 2024).
DOI:	10.7759/cureus.53334
Abstrakt:	This retrospective study aims to evaluate the safety of everolimus when used as part of the immunosuppression regimen in patients who underwent liver transplant from 2009 to 2019 at a tertiary liver transplant center. Patients were divided into two groups: those who received everolimus as part of the post-transplant regimen and those who did not. The primary safety outcome measured was the development of new pulmonary complications that had been associated with everolimus use in prior studies. Lung function was determined by pulmonary function tests if available or CT scans of the chest. Secondary outcomes measured included everolimus discontinuation rates and survival rates. During the study period, 450 patients underwent liver transplant; 35% of patients received everolimus (n=156) and 65% of patients did not receive everolimus (n=292). Primary safety outcome of pulmonary complications was seen in 3.9% of patients who received everolimus (n=6) and 6.3% of the control group patients who did not receive everolimus (n=19). The association between everolimus use and new pulmonary complications was not significant with a chi-square statistic of 1.33 (p=0.249). Overall, 51.3% of patients who received everolimus during their post-transplant course discontinued the medication (n=80). Everolimus is safe from a pulmonary toxicity standpoint in liver transplant immunosuppression regimens as there was no significant difference found in pulmonary complications between patients who received the medication and those who did not. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Obri et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu